Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1465-1473

  Parmigiani, Giovanni ^a   Berry, Donald A ^a   Winer, Eric P ^a   Tebaldi, Claudia ^a   Iglehart, J Dirk ^a   Prosnitz, Leonard R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SIZE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DECISION MAKING; FEMALE; HUMAN; LIFE EXPECTANCY; LYMPHADENECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT PLANNING;

EID: 0032948554     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1465     Document Type: Article

References (34)

1. Fisher B, Redmond C, Fisher ER: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-681, 1985
2. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992
3. Early Breast Cancer Trialists Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
4. Cady B: Is axillary lymph node dissection necessary in the routine management of breast cancer? No. Important Adv Oncol 251-256, 1996
5. Moore MP, Kinne DW: Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. Important Adv Oncol 245-250, 1996
6. Haffty B, Ward B, Pathare P, et al: Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 15:691-700, 1997
7. Silverstein MJ, Gierson ED, Waisman JR, et al: Axillary lymph node dissection for T1a breast carcinoma: Is it indicated? Cancer 73:664-667, 1994
8. Epstein RJ: Routine or delayed axillary dissection for primary breast cancer? Eur J Cancer 31A:1570-1573, 1995
9. Early Breast Cancer Trialists Collaborative Group: Effects of radiotherapy and surgery in early breast cancer. N Engl J Med 333:1444-1455, 1995
10. Lin PP, Allison DC, Wainstock J, et al: Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 11:1536-1544, 1993
11. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24,740 cases of breast cancer. Cancer 63:181-187, 1989
12. Recht A, Houlihan MJ: Axillary lymph nodes and breast cancer: A review. Cancer 76:1491-1512, 1995
13. Wood W, Weiss R, Tormey D, et al: A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study. World J Surg 9:714-718, 1985
14. Perloff M, Norton L, Korzun A, et al: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: A cancer and Leukemia Group B study. J Clin Oncol 14:1589-98, 1996
15. Wood W, Budman D, Korzun A, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
16. Rosen P, Groshen S, Saigo P, et al: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355-366, 1989
17. Quiet CA, Ferguson DJ, Weichelsbaum RR, et al: Natural history of node-negative breast cancer. J Clin Oncol 15:1144-1151, 1995
18. Thernau TM: A Package for Survival Analysis in S. Rochester, Minnesota, Mayo Foundation, 1996
19. Early Breast Cancer Trialists Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
20. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
21. Haffty BG, Fischer D, Fischer JJ: Regional nodal irradiation in the conservative treatment of breast cancer. Int J Radiat Oncol Biol Phys 19:859-865, 1990
22. Pliskin JS, Shepard D, Weinstein MC: Utility functions for life years and health status: Theory, assessment, and application. Oper Res 28:206-224, 1980
23. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 114:621-628, 1991
24. Halsted WS: The result of operations for the cure of the breast performed at the Johns Hopkins hospital from June 1889 to January 1894. Johns Hopkins Hosp Bull 4:279, 1894-1895
25. Keynes G: Conservative treatment of cancer of the breast. Br Med J 2:643-647, 1936
26. Johansen H, Kaae S, Scheiodt T: Simple mastectomy with postoperative irradiation vs. extended radical mastectomy in breast cancer. Acta Oncol 29:709-715, 1990
27. Morris A, Morris R, Wilson J, et al: Breast conserving therapy vs. mastectomy in early stage breast cancer: A meta-analysis of ten years survival. Cancer J 3:6-12, 1997
28. Quiet C, Ferguson D, Weichelsbaum RR, et al: Natural history of node-negative breast cancer: The curability of small cancers with a limited number of positive nodes. J Clin Oncol 14:3105-3111, 1996
29. Ivens D, Hoe A, Podd T, et al: Assessment of morbidity from complete axillary dissection. Br J Cancer 66:136-138, 1992
30. Goss P, Hack T, Cohen I, et al: Long-term physical and psychological morbidity of axillary node dissection in patients with breast cancer. Proc Am Soc Clin Oncol 15:123, 1996 (abstr)
31. Chu L, Bowen G, Peterson B, et al: Long-term complications following axillary node dissection (alnd). Proc Am Soc Clin Oncol 15:153, 1996 (abstr)
32. Velanovich V: Axillary lymph node dissection for breast cancer: A decision analysis of T1 lesions. Ann Surg Oncol 5:131-139, 1998
33. Giuliano A, Kirgan D, Guenther J, et al: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391-398, 1994
34. Albertini JJ, Lyman GH, Cox C, et al: Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818-1822, 1996